Page last updated: 2024-08-24

valsartan and Obesity

valsartan has been researched along with Obesity in 31 studies

Research

Studies (31)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (35.48)29.6817
2010's17 (54.84)24.3611
2020's3 (9.68)2.80

Authors

AuthorsStudies
Chou, CL; Fang, TC; Li, CH1
Chen, CH; Chen, CJ; Fang, JY; Huang, TH; Lin, HA1
Aroor, AR; Chandrasekar, B; Das, N; DeMarco, VG; Habibi, J; Jia, G; Lastra, G; Lopez-Alvarenga, JC; Mummidi, S1
Brink, D1
Albrecht, D; Blaak, EE; Engeli, S; Goossens, GH; Hartmann, N; Havekes, B; Heise, T; Jax, T; Jocken, JW; Jordan, J; Kaiser, S; Langenickel, TH; Letzkus, M; May, M; Schaper, N; Schindler, C; Stinkens, R; van der Kolk, BW1
Kitzman, DW; Packer, M1
Hasan, AU; Hashimoto, T; Ishihara, N; Ishihara, Y; Kamitori, K; Kohno, M; Noma, T; Ohmori, K; Tokuda, M; Yamaguchi, F1
Ambrosio, G; Anker, SD; Díez, J; Edelmann, F; Filippatos, GS; Fraser, AG; Gavazzi, A; Gheorghiade, M; Guazzi, M; Hummel, SL; Lam, CS; Levy, D; Maggioni, AP; Metra, M; Paulus, WJ; Pfeffer, MA; Pieske, BM; Senni, M; Smiseth, OA; Solomon, SD; Stewart Coats, AJ; Stough, WG; Tschöpe, C1
Akkaya, N; Cakmak, M; Çelik, HT; Demircelik, B; Erdamar, H; Gok, S; Kazanci, F; Yigitoglu, R1
Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Santoro, T; Zoppi, A1
Brown, RE; Imran, SA; Wilkinson, M1
Deedwania, PC; Egan, BM; Jialal, I; Ofili, EO; Purkayastha, D; Raij, L; Samuel, R; Sowers, JR; Zappe, DH1
Rudolph, A; Weintraub, HS1
Akhtari, S; Andalib, A; Curnew, G; Leclerc, JM; Rigal, R; Tardif, JC; Vaillancourt, M1
Circelli, M; Cremonesi, G; Fogari, R; Mugellini, A1
Matsuura, K; Mori, Y; Tanaka, T; Utsunomiya, K; Yokoyama, J1
Dralova, OV; Ermolaeva, AS; Maksimov, ML1
Egan, BM; Purkayastha, D; Raij, L; Samuel, R; Sowers, JR; Zappe, DH1
Han, G; Lieberman, K; Meyers, KE; Shi, V; Solar-Yohay, S1
Biskupiak, J; Qian, C; Quah, R; Ram, CV; Ramaswamy, K; Russo, PA; Ryan, A1
Goto, SN; Mizuno, Y; Takagi, H; Umemoto, T; Yamamoto, H1
Ambrosi, P; Andrejak, M; Drici, MD; Herpin, D; Pithois-Merli, I1
Bönner, G; Heintz, D; Kandra, A; Khder, Y; Malacco, E; Ruilope, LM1
Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A1
Boschmann, M; Engeli, S; Jordan, J; Kreuzberg, U; Luft, FC; Sharma, AM; Weidinger, G1
Hirata, Y; Hirono, Y; Sugiyama, T; Tateno, T; Tsuchiya, K; Yoshimoto, T1
Adams, F; Boschmann, M; Engeli, S; Franke, G; Jordan, J; Klaua, S; Kreuzberg, U; Luft, FC; Scholze, J; Sharma, AM; Weidinger, G1
Itoh, Y; Mori, Y; Tajima, N1
Davidson, J; Koval, S; Lacourcière, Y; Sharma, AM1
Horiuchi, M; Inaba, S; Iwai, M; Mogi, M; Tomono, Y1
Dunseath, G; Luzio, SD; Owens, DR1

Reviews

8 review(s) available for valsartan and Obesity

ArticleYear
Heart failure treatment: Keeping up with best practices.
    The Journal of family practice, 2018, Volume: 67, Issue:1

    Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Cardiac Rehabilitation; Cardiac Resynchronization Therapy; Cardiovascular Agents; Defibrillators, Implantable; Diuretics; Drug Combinations; Echocardiography; Heart Failure; Heart-Assist Devices; Humans; Ivabradine; Obesity; Physician's Role; Physicians, Family; Sleep Apnea, Obstructive; Stroke Volume; Tetrazoles; Valsartan

2018
Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2.
    JACC. Heart failure, 2018, Volume: 6, Issue:8

    Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Drug Therapy, Combination; Glucosides; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Neprilysin; Obesity; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan

2018
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.
    European heart journal, 2014, Oct-21, Volume: 35, Issue:40

    Topics: Aminobutyrates; Anemia; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Biphenyl Compounds; Cardiotonic Agents; Clinical Trials as Topic; Diabetic Angiopathies; Diuretics; Drug Combinations; Exercise Therapy; Heart Failure; Homeostasis; Humans; Hypertension, Pulmonary; Iron Deficiencies; Mineralocorticoid Receptor Antagonists; Molecular Targeted Therapy; Obesity; Observational Studies as Topic; Patient Selection; Phenotype; Phosphodiesterase 5 Inhibitors; Sodium Channel Blockers; Stroke Volume; Tetrazoles; Valsartan; Vascular Stiffness

2014
Combination therapy for managing difficult-to-treat patients with stage 2 hypertension: focus on valsartan-based combinations.
    American journal of therapeutics, 2011, Volume: 18, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Black or African American; Calcium Channel Blockers; Diuretics; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Obesity; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan

2011
Combination delapril/manidipine as antihypertensive therapy in high-risk patients.
    Clinical drug investigation, 2011, Volume: 31, Issue:7

    Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Diabetes Complications; Dihydropyridines; Drug Combinations; Enalapril; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Indans; Irbesartan; Losartan; Nitrobenzenes; Obesity; Olmesartan Medoxomil; Piperazines; Ramipril; Tetrazoles; Valine; Valsartan

2011
[Hypertension, obesity, erectile dysfunction. What kind of drug to choose].
    Kardiologiia, 2011, Volume: 51, Issue:7

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Erectile Dysfunction; Humans; Hypertension; Male; Obesity; Renin-Angiotensin System; Risk Factors; Tetrazoles; Valine; Valsartan

2011
Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2013, Volume: 36, Issue:4

    Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channel Blockers; Confidence Intervals; Cross-Over Studies; Double-Blind Method; Humans; Hypertension; Hypertension, Renal; Imidazoles; Interleukin-6; Obesity; Prospective Studies; Publication Bias; Randomized Controlled Trials as Topic; Stents; Telmisartan; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan

2013
[The best of clinical pharmacology in 2004].
    Archives des maladies du coeur et des vaisseaux, 2005, Volume: 98 Spec No 1

    Topics: Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Diabetes Complications; Humans; Obesity; Tetrazoles; Valine; Valsartan

2005

Trials

13 trial(s) available for valsartan and Obesity

ArticleYear
The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients.
    Scientific reports, 2018, 03-02, Volume: 8, Issue:1

    Topics: Adipose Tissue; Adult; Aminobutyrates; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Humans; Hypertension; Male; Middle Aged; Neprilysin; Obesity; Proteins; Subcutaneous Fat; Tetrazoles; Transcriptome; Valsartan

2018
The Effects of Valsartan and Amlodipine on the Levels of Irisin, Adropin, and Perilipin.
    Clinical laboratory, 2015, Volume: 61, Issue:12

    Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Proteins; Calcium; Carrier Proteins; Female; Fibronectins; Humans; Hypertension; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Obesity; Peptides; Perilipin-1; Phosphoproteins; Valsartan

2015
Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients.
    Internal medicine (Tokyo, Japan), 2008, Volume: 47, Issue:21

    Topics: Adult; Aged; Amlodipine; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Hypertension; Insulin; Male; Middle Aged; Obesity; Overweight; Prospective Studies; Tetrazoles; Valine; Valsartan

2008
Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives.
    Journal of hypertension, 2010, Volume: 28, Issue:8

    Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Body Mass Index; Calcium Channel Blockers; Diuretics; Drug Therapy, Combination; Female; Glucose Tolerance Test; Humans; Hydrochlorothiazide; Hypertension; Insulin; Male; Middle Aged; Obesity; Tetrazoles; Treatment Outcome; Valine; Valsartan

2010
Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE).
    Advances in therapy, 2011, Volume: 28, Issue:8

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Blood Pressure; Female; Glucose; Glucose Tolerance Test; Humans; Hyperinsulinism; Hypertension; Insulin Resistance; Male; Obesity; Telmisartan; Tetrazoles; Valine; Valsartan

2011
Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs. hydrochlorothiazide-based therapy in obese, hypertensive patients.
    Journal of clinical hypertension (Greenwich, Conn.), 2011, Volume: 13, Issue:10

    Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Obesity; Office Visits; Tetrazoles; Treatment Outcome; Valine; Valsartan

2011
The efficacy and safety of valsartan in obese and non-obese pediatric hypertensive patients.
    Journal of clinical hypertension (Greenwich, Conn.), 2011, Volume: 13, Issue:10

    Topics: Adolescent; Antihypertensive Agents; Blood Pressure; Child; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; International Cooperation; Male; Obesity; Tetrazoles; Treatment Outcome; Valine; Valsartan

2011
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Clinical therapeutics, 2005, Volume: 27, Issue:5

    Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Obesity; Risk Factors; Tetrazoles; Valine; Valsartan

2005
Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2005, Volume: 28, Issue:3

    Topics: Aged; Antihypertensive Agents; Felodipine; Female; Humans; Hypertension; Insulin Resistance; Leptin; Male; Middle Aged; Obesity; Tetrazoles; Treatment Outcome; Valine; Valsartan

2005
Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients.
    Journal of hypertension, 2005, Volume: 23, Issue:12

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hypertension; Lipids; Male; Middle Aged; Obesity; Sodium Chloride Symporter Inhibitors; Tetrazoles; Valine; Valsartan

2005
The effect of oral glucose loads on tissue metabolism during angiotensin II receptor and beta-receptor blockade in obese hypertensive subjects.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2006, Volume: 38, Issue:5

    Topics: Adipose Tissue; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Ethanol; Fatty Acids, Nonesterified; Female; Glucose; Glucose Tolerance Test; Glycerol; Humans; Hypertension; Insulin; Kinetics; Lactic Acid; Lipids; Male; Metabolism; Middle Aged; Muscle, Skeletal; Obesity; Tetrazoles; Valine; Valsartan

2006
Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study.
    Cardiovascular diabetology, 2007, Oct-02, Volume: 6

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Diastole; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Male; Middle Aged; Obesity; Placebos; Single-Blind Method; Systole; Telmisartan; Tetrazoles; Valine; Valsartan

2007
Acute effects of valsartan on insulin sensitivity in obese, non-hypertensive subjects with and without type 2 diabetes.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2002, Volume: 34, Issue:5

    Topics: Adolescent; Adult; Antihypertensive Agents; Cross-Over Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Obesity; Tetrazoles; Valine; Valsartan

2002

Other Studies

10 other study(ies) available for valsartan and Obesity

ArticleYear
Benefits of Valsartan and Amlodipine in Lipolysis through PU.1 Inhibition in Fructose-Induced Adiposity.
    Nutrients, 2022, Sep-12, Volume: 14, Issue:18

    Topics: Activating Transcription Factor 3; Adiposity; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Fructose; Humans; Hypertension; Lipase; Lipolysis; Monoacylglycerol Lipases; Obesity; Stearoyl-CoA Desaturase; Tetrazoles; Triglycerides; Valsartan

2022
Self-Nanoemulsifying Drug Delivery System-Containing the Poorly Absorbed Drug - Valsartan in Post-Bariatric Surgery.
    International journal of nanomedicine, 2023, Volume: 18

    Topics: Animals; Bariatric Surgery; Caco-2 Cells; Drug Delivery Systems; Humans; Obesity; Pharmaceutical Preparations; Valsartan

2023
Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
    Cardiovascular diabetology, 2021, 04-21, Volume: 20, Issue:1

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cytokines; Diabetic Cardiomyopathies; Diastole; Disease Models, Animal; Drug Combinations; Male; Myocardium; Neprilysin; Obesity; Protease Inhibitors; Rats, Zucker; Valsartan; Vascular Stiffness; Ventricular Dysfunction, Left; Ventricular Function, Left

2021
Valsartan ameliorates the constitutive adipokine expression pattern in mature adipocytes: a role for inverse agonism of the angiotensin II type 1 receptor in obesity.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2014, Volume: 37, Issue:7

    Topics: 3T3-L1 Cells; Active Transport, Cell Nucleus; Adipocytes; Adipokines; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Chlorocebus aethiops; COS Cells; Drug Inverse Agonism; Interleukin-6; Mice; NF-kappa B; Obesity; PPAR gamma; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan

2014
Tissue-specific effects of valsartan on rstn and fiaf gene expression in the ob/ob mouse.
    Diabetes & vascular disease research, 2010, Volume: 7, Issue:3

    Topics: Angiopoietin-Like Protein 4; Angiopoietins; Angiotensin II Type 1 Receptor Blockers; Animals; Cerebral Cortex; Diabetes Mellitus; Disease Models, Animal; Gene Expression Regulation; Hypothalamus; Intra-Abdominal Fat; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Pituitary Gland; Resistin; RNA, Messenger; Subcutaneous Fat; Tetrazoles; Time Factors; Valine; Valsartan

2010
Determinants of masked hypertension in hypertensive patients treated in a primary care setting.
    Internal medicine journal, 2012, Volume: 42, Issue:3

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; Comorbidity; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; Female; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Male; Masked Hypertension; Middle Aged; Obesity; Prevalence; Primary Health Care; Quebec; Risk; Tetrazoles; Valine; Valsartan; White Coat Hypertension

2012
Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.
    Journal of clinical hypertension (Greenwich, Conn.), 2011, Volume: 13, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Black or African American; Blood Pressure; Diabetes Mellitus; Electronic Health Records; Female; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Obesity; Primary Health Care; Retrospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan; White People; Young Adult

2011
Angiotensin II induces monocyte chemoattractant protein-1 expression via a nuclear factor-kappaB-dependent pathway in rat preadipocytes.
    American journal of physiology. Endocrinology and metabolism, 2006, Volume: 291, Issue:4

    Topics: Adipocytes; Adipose Tissue; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Cell Differentiation; Chemokine CCL2; Humans; Male; NF-kappa B; Nitriles; Obesity; Promoter Regions, Genetic; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfones; Tetrazoles; Thiocarbamates; Transcription, Genetic; Valine; Valsartan

2006
Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity.
    American journal of hypertension, 2007, Volume: 20, Issue:4

    Topics: Adipocytes; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Calcium Channel Blockers; Cell Size; Diabetes Mellitus, Type 2; Disease Models, Animal; Insulin; Intra-Abdominal Fat; Male; Obesity; PPAR gamma; Random Allocation; Rats; Rats, Long-Evans; Telmisartan; Tetrazoles; Valine; Valsartan

2007
Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models.
    American journal of hypertension, 2008, Volume: 21, Issue:2

    Topics: Adipocytes, White; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Cell Differentiation; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Gene Deletion; Gene Expression; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Obesity; PPAR gamma; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan

2008